Day: November 26, 2024

Basel, 26 November 2024 – Roche (SIX: RO, ROG; OTCQX: RHHBY) reports an update on the phase III SKYSCRAPER-01 study, evaluating tiragolumab combined with Tecentriq® (atezolizumab) compared to Tecentriq alone for patients with PD-L1-high, locally advanced or metastatic non-small cell lung cancer (NSCLC).  SKYSCRAPER-01 is a global phase III, randomised, double-blind study evaluating tiragolumab plus Tecentriq compared to Tecentriq alone in 534 patients with PD-L1-high previously untreated, locally advanced unresectable or metastatic NSCLC. Patients were randomised 1:1 to receive either tiragolumab plus Tecentriq or placebo plus Tecentriq, until disease progression, loss of clinical benefit, or unacceptable toxicity. The study did not reach the primary endpoint of overall survival at the final analysis. The overall safety profile observed...

The Management Board of AB Kauno Energija (hereinafter – the Company) (code – 235014830) assessed the results of Company’s business activity of 9 months of the year 2024 and financial state as at September 30, 2024 and approved AB Kauno Energija consolidated and Company’s non-audited results of 9 months of the year 2024. The result of Company’s business activities of 9 months of the year 2024 according to the International Financial Reporting Standards as adopted by the European Union is profit in amount of EUR 954 thousand (the result of 9 months of the year 2023 was profit amounted to EUR 534  thousand), turnover from sales is EUR 53,657 thousand (in 9 months of the year 2023 it was amounted to EUR 56,210 thousand). The result of activities of the Group which consists of AB Kauno Energija and its’ subsidiaries UAB GO Energy LT (code...

Havila Kystruten AS will publish its Q3 2024 financial report on Wednesday, November 27, 2024. Bent Martini, CEO, and Aleksander Røynesdal, CFO, will present the results in an earnings call at 10:00 CET on Thursday, November 28, 2024, followed by a Q&A session. The earnings call can be accessed live via webcast. A recording will be available on demand at the Company’s website after the live event has concluded. The earnings call can be accessed through the following link: https://www.appairtime.com/event/822ef1cf-43da-4636-b027-e301921f578b Contacts: Chief Executive Officer: Bent Martini, +47 905 99 650 Chief Financial Officer: Aleksander Røynesdal, +47 413 18 114   This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Oslo, 26 November 2024: In the third quarter, Vow ASA (“Vow” or the “Company”) (OSE ticker: VOW) had revenues of NOK 267.4 million, representing an increase of 5.0 percent relative to the third quarter in 2023. EBITDA before non-recurring items was NOK 18.4 million, resulting in an EBITDA margin of 6.9 per cent, compared to negative NOK 15.5 million in the third quarter last year. The Vow group has continued to deliver on cost reduction programmes. For the full year 2024, annual cost savings are estimated to be in the range of NOK 40-50 million compared to full year 2023. “This is the third consecutive quarter with a positive EBITDA result and we are working our way back after a challenging period. The positive trend this year is a result of our wide-ranging efforts to improve the gross margin in projects,...

SANTA MONICA, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) — The Macerich Company (NYSE: MAC) (the “Company” or “Macerich”) announced today that it has priced an underwritten public offering of 20,000,000 shares of common stock at a price to public of $19.75 per share for expected gross proceeds of approximately $395.0 million. The Company has also granted the underwriters a 30-day option to purchase up to 3,000,000 additional shares of its common stock. This reflects an upsizing of the previously announced offering of 18,000,000 shares of common stock. Subject to customary closing conditions, the offering is expected to close on November 27, 2024. The Company intends to use the net proceeds of this offering, together with cash on hand, including from recent sales under the Company’s “at the market” offering program, to repay the $478.0...

Acquisition supports Roche’s Pharma Strategy and allows for a range of potentially first and best-in-class therapies across oncology, immunology, and neurology, uniquely positioning Roche in the new field of donor-derived off-the-shelf cell therapies Roche to acquire Poseida Therapeutics for US $9.00 per share in cash at closing, representing a total equity value of approximately US $1.0 billion Stockholders would also receive a non-tradeable contingent value right (CVR) for up to an aggregate of US $4.00 per share in cash, representing a total deal value of up to approximately US $1.5 billion The transaction is expected to close in the first quarter of 2025Basel, 26 November 2024 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has entered into a definitive merger agreement to acquire Poseida Therapeutics, Inc. (“Poseida”,...

NACON STUDIO GHENT ANNOUNCES HUNTING SIMULATOR 3 Belgian studio Neopica becomes NACON Studio Ghent and reveals its new project Lesquin, 26 November 2024 – NACON and NACON Studio Ghent are pleased to announce Hunting Simulator 3, a new simulation that will delight hunting enthusiasts. Explore the natural landscapes of Colorado and Texas, alone or in a group, and hunt numerous animal species with the help of your faithful hunting dog, when the game launches soon for PlayStation®5, Xbox Series X|S and PC (Steam). Check out the Announcement Trailer: https://youtu.be/kdgO9IDeUxc With almost 10 years’ expertise in hunting games, the studio intends to offer fans of the genre an authentic hunting experience with this third opus. Thanks to feedback from the community, which numbered over 1 million players on the two previous titles, NACON...

Wilmington, DE, Nov. 25, 2024 (GLOBE NEWSWIRE) — Charlton Aria Acquisition Corporation (the “Company”) (Nasdaq: CHARU), a blank check company, today announced that, commencing on November 26, 2024, holders of the 8,500,000 units (the “Units”) sold in the Company’s initial public offering (the “Offering”) including Units sold upon a partial exercise of the underwriters’ over-allotment option, may elect to separately trade the Class A ordinary shares and rights included in the Units. Any Units not separated will continue to trade on the NASDAQ Global Market (“NASDAQ”) under the symbol “CHARU.” Any underlying Class A ordinary shares and rights that are separated will trade on the NASDAQ under the symbols “CHAR” and “CHARR,” respectively. Holders of Units will need to have their brokers contact the Company’s transfer agent, Continental...